ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Cyclerion Announces Sickle Cell Disease Study Results americanpharmaceuticalreview
October 22, 2020Cyclerion Therapeutics announced top-line results from its STRONG-SCD study of olinciguat, an investigational, orally-administered, once daily, vascular sGC stimulator for the potential treatment of sickle cell disease (SCD).
Pharma Sources Insight January 2025
